Author:
Hoentjen Frank,Bodegraven Ad A van
Publisher
Baishideng Publishing Group Inc.
Subject
Gastroenterology,General Medicine
Reference59 articles.
1. Hoentjen F, Dieleman LA. Pathophysiology of inflammatory bowel diseases. Handbook of prebiotics Boca Raton: CRC Press; 2008;341-374.
2. Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006;64:219-229.
3. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther 2006;23:451-463.
4. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
5. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献